Mobile health apps raised $220 million in Q1 2015. And the financial backers were ambitious. Fitness, nutrition and wellness apps accounted for only 17% of the total, while advanced apps to treat chronic conditions and illnesses took 77% of the pie.
Remember the days when Biogen's Tecfidera was trumping analyst expectation after analyst expectation? Well, they're in the past--at least for now.
AstraZeneca CEO Pascal Soriot, while fighting off the takeover attempt by Pfizer, promised that the company would hit annual revenue of $45 billion by 2023. Now he will be measured by that promise quarter by quarter and today he fell a little short.
C.R. Bard reported increased first-quarter sales as its Lutonix drug-coated balloons used to treat peripheral artery disease (PAD) in outpatients help lift the company's earnings.
Indianapolis-based Eli Lilly said Thursday that it earned 87 cents per share in the first quarter of 2015--10 cents more than analysts had expected--an achievement the company attributed largely to its $5.4 billion acquisition of Novartis Animal Health.
Shanghai Haohai Biological Technology has priced its Hong Kong initial public offering at the top end of an indicative price range of HK$48.50 to HK$59 per share to raise $305 million, better than the $263 million (HK$2.0 billion) expected, according to a source.
As of 2014, Teva is in the No. 11 spot on the list of pharma's top revenue generators. But if it gets its way and lands a deal for rival generics maker Mylan, just how much will it be moving up the charts?
Inspire Medical Systems snagged approval to provide its implantable sleep apnea device at U.S. military and veterans' hospitals, a win for the company as it looks to ramp up commercialization for the product and gain coveted reimbursement.
AbbVie's working toward solutions to protect its top line against Humira's inevitable decline. For now, though, its workhorse is still getting the job done, and it delivered yet another double-digit leap in Q1 to help the company beat expectations.
Eli Lilly faced its fair share of problems last year, struggling with slumping sales and patent expirations for two of its bestselling products. But Lilly is celebrating a bright point, bringing in Q1 2015 numbers boosted by the success of its recently acquired animal health unit.